Week in Review: Three China In-Licensing Deals Add up to $662 Million

Deals and Financings   Simcere Pharma of  Nanjing  announced a $292 million agreement to develop a Kazia Therapeutics candidate for glioma in Greater China; LianBio, a Shanghai-Princeton biopharma, formed a $200 million collaboration to develop two Tarsus Pharma ophthalmology drugs in Greater China; AffaMed Therapeutics of  Shanghai  closed a $170 million Series B financing to develop treatments for ophthalmic, neurological and psychiatric disorders; Immune-Onc Therapeutics of Palo Alto , CA raised $73 million in a Series B1 and B2 financing led by China's Oceanpine Capital for its novel immunotherapies; Hangzhou Qihan Biotechnology raised $67 million in a Series A++ round to advance its portfolio of novel gene edited autologous cell therapies; Neuracle Technology ( Changzhou ) closed a Series B funding of $16 million to advance development of its brain-machine interface technologies;   COVID-19 Pandemic   Jiangxi Jemincare Group was approved to start US clinical trials of its SARS-CoV-2 neutralizing antibody, following the start of China Phase I trial in January; Beijing 's Sinovac reported that it now has the ability to manufacture two billion doses annually of its inactivated COVID-19 vaccine;  Trials and Approvals   Zai Lab announced China's NMPA approved Qinlock® (ripretinib) to launch as a fourth-line treatment for advanced GIST (gastrointestinal stromal tumors);  CStone Pharma of  Suzhou  was approved to launch avapritinib tablets, a treatment for unresectable/metastatic GIST with a specific genetic biomarker; New York City 's BeyondSpring submitted NDAs to US and  China  regulators for a novel neutropenia treatment; Shanghai Henlius Biotech will file for  China  approval of its PD-1 inhibitor after successful Phase II trials of the candidate; Everest Medicines of Shanghai was approved to conduct a China Phase II trial of a TROP-2 inhibitor in patients with solid tumor cancers;  Company News   Hangzhou 's Ascletis Pharma will expand from its original focus on hepatitis C treatments to also develop oncology products.  Stock Symbols: (HK: 2096) (ASX: KZA; NSDQ: KZIA) (NSDQ: TARS) (NSDQ: ZLAB; HK: 9688) (NSDQ: SVA) (HK: 2616) (NSDQ: BYSI) (HK: 2696) (HK: 1952) (HK: 1672) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.